Patent applications published 9 February 2011
Selected patent applications from the weekly European Patents Bulletin
- Stable crystal modifications of DOPC
 Merck Patent 2280691*
 
- Tablet comprising eprosartan mesylate
 LEK Pharmaceuticals 2280692*
 
- Liquid and freeze-dried formulations
 Ipsen Pharma 2280693*
 
- Humidity-resistant drug formulations and methods of preparation thereof
 Dexcel Pharma Technologies 2280694*
 
- Hydroxytyrosol benefits mitochondria
 DSM IP Assets 2280695*
 
- Modulators of the prostacyclin (PGI2) receptor useful for the treatment of diseases related thereto
 Arena Pharmaceuticals 2280696*
 
- Oral liquid compsns of rhein or diacerein
 Wockhardt Research Centre 2280697*
 
- Method for inhibiting the growth of bacteria
 Mead Johnson Nutrition Co 2280698*
 
- Novel estrogen receptor ligands
 Karo Bio 2280699*
 
- Combinations of dronedarone with at least one diuretic, and therapeutic use thereof
 Sanofi-Aventis 2280700*
 
- Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalisation or of mortality
 Sanofi-Aventis 2280701*
 
- Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood
 Sanofi-Aventis 2280702*
 
- Use of NPY Y5 receptor antagonists for the prevention of psychostimulant and opioid abuse
 University of Copenhagen 2280703*
 
- Oxymethylene aryl compounds and uses thereof
 Metabolex 2280704*
 
- Novel compounds
 Glaxo Group 2280705*
 
- Lipoprotein lipase activating compsns comprising benzene derivatives
 Otsuka Pharmaceutical Factory 2280706*
 
- Alpha2B and alpha2C agonists
 Allergan 2280707*
 
- MMP-2 and/or MMP-9 inhibitor
 Otsuka Pharmaceutical 2280708*
 
- Treatment of hepatitis C virus infections with telaprevir (VX-950) in patients non-responsive to treatment with pegylated interferon-alpha-2A/2B and ribaviron
 Vertex Pharmaceuticals 2280709*
 
- Novel treatment of heart diseases
 Axiogenesis 2280710*
 
- Methods, dosage form and kits for administering ziprasidone without food
 Pfizer 2280711*
 
- Fluocinolone formulations in a biodegradable polymer carrier
 Warsaw Orthopedic; Medtronic 2280712*
 
- Methods and kits for the treatment of inflammatory bowel disorder conditions
 Procter & Gamble 2280713*
 
- Compsns comprising anrnox-inhibitors for the inhibition of active oxygen species
 Nu Skin International; NOX Technologies 2280714*
 
- Silicia for the inhibition of a protease
 Ineos Healthcare 2280715*
 
- Agents and methods for treatment of anxiety disorders
 Yeda Research and Development Co at the Weizmann Institute of Science 2280716*
 
- Therapeutic agent for anaerobic diseases
 Anaeropharma Science 2280717*
 
- Extracts from plants of the tsuga genus and uses thereof in the treatment of inflammation, irritation and/or infection
 Biopharmacopae Design International 2280718*
 
- Therapeutic use of at least one botulinum neurotoxin in the treatment of pain associated with diabetic neuropathy
 Ipsen Pharma 2280719*
 
- Collagen-binding synthetic peptidoglycans, preparation and methods of use
 Purdue Research Foundation 2280720*
 
- Indoleamine 2,3-dioxygenase based immunotherapy
 Herlev Hospital 2280721*
 
- Method of treating degenerative diseases
 Orthologic 2280722*
 
- Zona pellucisa binding peptides, expression vectors, compsns and methods for species-specific immunocontraception of animals
 Auburn University 2280723*
 
- Compsns for treating an inflammatory autoimmune condition
 TXCell 2280724*
 
- Antiviral nutraceutical
 Marine Biotechnology Australia 2280726*
 
- Vaccine compsns for the treatment of dengue fever and uses thereof
 Cytos Biotechnology 2280727*
 
- Combined measles-human papilloma vaccine
 Cadila Healthcare 2280728*
 
- Method to design and uses of overlapping peptides for monitoring T-cell responses in HIV patients
 Fondazione Centro San Raffaele del Monte Tabor; Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt 2280730*
 
- Anti-human immunodeficiency antibodies and uses thereof
 Tecnion Research and Development Foundation 2280731*
 
- Antibodies to granulocyte-macrophage colony-stimulating factor
 Kalabios Pharmaceuticals 2280732*
 
- Maintenance therapy regimen for treating acne
 Galderma Research & Development 2280733*
 
- Factor IX conjugates with extended half-lives
 Celtic Pharma Peg 2280734*
 
- Agents for detecting and imaging cell death
 Cambridge Enterprise 2280735*
 
- Fatty acid imides and uses thereof
 Yissum Research Development Co of the Hebrew University of Jerusalem 2280934*
 
- 4-trimethylammonio-butyrates as CPT2 inhibitors
 F Hoffmann-La Roche 2280935*
 
- Ether-amide type compounds, preparation method and uses
 Rhodia Operations 2280936*
 
- Aliskiren monofumarate and processes for preparation thereof
 Teva Pharmaceutical Industries 2280937*
 
- A process for preparing teriflunomide
 Alembic 2280938*
 
- Novel N-(2-amino-phenyl)-acrylamides
 F Hoffmann-La Roche 2280940*
 
- (Hetero)aryl cyclohexane derivatives
 Grünenthal 2280941*
 
- Indolesulphonyl protecting groups for protection of guanidino and amino groups
 Lonza 2280942*
 
- New substituted spiro(cycloalkyl-1,3’-indol)-2’(1’H)-one derivatives and their use as P38 mitogen-activated kinase inhibitors
 Almirall 2280943*
 
- Process for the preparation of amides
 Syngenta 2280944*
 
- Trisubstituted pyrazoles as acetylcholine receptor modulators
 Janssen Pharmaceutica 2280945*
 
- 4-carboxamide indazole derivatives useful as inhibitors of P13-kinases
 Glaxo Group 2280946*
 
- Production of 1,7’-dimethyl-2’-propyl-2,5’-bi-1H-benzimidazole
 Boehringer Ingelheim International 2280947*
 
- Pyrimidine, pyridine and triazine derivatives as maxi-K channel openers
 Mitsubishi Tanabe Pharma 2280948*
 
- Process for the preparation of benzo-fused heteroaryl sulphamates and crystalline form of N-((2S)-6-chloro-2,3-dihydro-L,4-benzodioxin-2-yl) methyl sulphamide
 Janssen Pharmaceutica 2280950*
 
- Processes for the preparation of benzo-fused dioxin derivatives
 Janssen Pharmaceutica 2280951*
 
- Thienopyridione derivatives as AMP-activated protein kinase (AMPK) activators
 Merck Patent 2280952*
 
- New substituted indolin-2-one derivatives and their use as P38 mitogen-activated kinase inhibitors
 Almirall 2280953*